Modelling the impact of PCSK9 inhibitors on lipoproteins in patients with dyslipidemia
Phase 4
- Conditions
- E78.5Hyperlipidaemia, unspecified
- Registration Number
- DRKS00011663
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Written consent
conditions for a therapy with PCSK9-inhibitors are given
Exclusion Criteria
1.severe Liver-disease g (Child-Pugh C) 2. severe renal insufficiency 3.TSH not im reference range 4. uncontrolled aterial hypertension: Diastolic RR >=105 mmHg and/or systolic RR >=160 mmHg. 5.alcohol abuse or other drug abuse (except smoking) 6. blood donation within the last 6 weeks before the screening 7. Patients with a severe acute disease 8.HbA1c > 8.0% 9. Other important severe internistic diseases, which may alter the lipidmetabolism 10.hypersensitivity against the substance 11.pregnancy oder planned pregnancy and lactation period
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method